摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(tert-butyl)-6-methylnicotinamide | 342417-08-7

中文名称
——
中文别名
——
英文名称
N-(tert-butyl)-6-methylnicotinamide
英文别名
N-tert.-butyl-6-methyl-nicotinamide;N-tert-butyl-6-methylpyridine-3-carboxamide
N-(tert-butyl)-6-methylnicotinamide化学式
CAS
342417-08-7
化学式
C11H16N2O
mdl
——
分子量
192.261
InChiKey
OUOGJYJUEDTLJJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    42
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    N-(tert-butyl)-6-methylnicotinamideO-甲苯基氯化镁2,3-二氯-5,6-二氰基-1,4-苯醌 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 24.0h, 以84%的产率得到N-tert-butyl-6-methyl-4-(o-tolyl)nicotinamide
    参考文献:
    名称:
    新型NK 1受体拮抗剂的高效合成:格氏试剂到6-氯烟酸衍生物的选择性1,4-加成。
    摘要:
    描述了从6-氯烟酸开始的两类新型NK 1受体拮抗剂的新有效合成方法,其中包括befetupitant和netupitant。o的介绍吡啶环C(4)上的甲苯基取代基是通过对6-氯烟酸或其衍生物的一锅选择性1,4-格里雅加成/氧化序列实现的。检查了该添加/氧化顺序的范围。还表明,可以通过霍夫曼重排然后还原将羧基官能团转化为甲基氨基。此外,建立了一种新的高产率合成2-(3,5-双三氟甲基苯基)-2-甲基丙酸的方法,该方法是通过将3,5-双(三氟甲基)溴苯加到丙酮中而获得的叔醇羰基化而合成的。 。
    DOI:
    10.1021/jo0523666
  • 作为产物:
    描述:
    6-甲基烟酸氯化亚砜N,N-二甲基甲酰胺 作用下, 以 甲苯 为溶剂, 反应 1.5h, 生成 N-(tert-butyl)-6-methylnicotinamide
    参考文献:
    名称:
    新型NK 1受体拮抗剂的高效合成:格氏试剂到6-氯烟酸衍生物的选择性1,4-加成。
    摘要:
    描述了从6-氯烟酸开始的两类新型NK 1受体拮抗剂的新有效合成方法,其中包括befetupitant和netupitant。o的介绍吡啶环C(4)上的甲苯基取代基是通过对6-氯烟酸或其衍生物的一锅选择性1,4-格里雅加成/氧化序列实现的。检查了该添加/氧化顺序的范围。还表明,可以通过霍夫曼重排然后还原将羧基官能团转化为甲基氨基。此外,建立了一种新的高产率合成2-(3,5-双三氟甲基苯基)-2-甲基丙酸的方法,该方法是通过将3,5-双(三氟甲基)溴苯加到丙酮中而获得的叔醇羰基化而合成的。 。
    DOI:
    10.1021/jo0523666
点击查看最新优质反应信息

文献信息

  • Method of inhibiting angiogenesis
    申请人:——
    公开号:US20040116479A1
    公开(公告)日:2004-06-17
    Compounds having the formula 1 are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
    具有以下化学式的化合物是抑制血管生成的抑制剂。还公开了含有这些化合物的组合物、制备这些化合物的方法以及使用这些化合物进行治疗的方法。
  • SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES
    申请人:Bayer Aktiengesellschaft
    公开号:US20200390100A1
    公开(公告)日:2020-12-17
    The present invention relates to substituted N-heterocyclyl- and N-heteroaryltetrahydropyrimidinones of the general formula (I) or salts thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to the use thereof as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the growth of crops of useful plants.
    本发明涉及通式(I)或其盐的取代N-杂环烷基和N-杂芳基四氢嘧啶酮,其中通式(I)中的基团对应于描述中给出的定义,并将其用作除草剂,特别是用于控制作物中的阔叶杂草和/或杂草草,并/或作为植物生长调节剂,以影响作物的生长。
  • 4-phenyl-pyridine derivatives
    申请人:——
    公开号:US20020091265A1
    公开(公告)日:2002-07-11
    The present invention relates to compounds of the general formula 1 R is lower alkyl, lower alkoxy, halogen or trifluoromethyl; R 1 is halogen or hydrogen; and when p is 1, R 1 in addition to the above substituents may be taken together with R 1 to form —CH═CH—CH═CH—, R 2 and R 2′ are independently hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; and when n is 1, R 2 and R 2′ may in addition to the above substituents form —CH═CH—CH═CH—, unsubstituted or substituted by one or two substituents selected from lower alkyl or lower alkoxy; R 3 and R 3′ are hydrogen, lower alkyl or taken together with the attached carbon atom form a cycloalkyl group; R 4 is hydrogen, —N(R 5 ) 2 , —N(R 5 )(CH 2 ) n OH, —N(R 5 )S(O) 2 -lower alkyl, N(R 5 )S(O) 2 -phenyl, —N═CH—N(R 5 ) 2 , —N(R 5 )C(O)R 5 ; 2 3 R 5 is hydrogen, C 3-6 -cycloalkyl, benzyl or lower alkyl; R 6 is hydroxy, lower alkyl; —(CH 2 ) n COO—(R 5 ), —N(R 5 )CO-lower alkyl, hydroxy-lower alkyl;—(CH 2 ) q CN; —(CH 2 ) n O(CH 2 ) n OH, —CHO or a 5-or 6 membered heterocyclic ring containing from 1 to 4 heteroatoms, selected from the group consisting of oxygen, nitrogen, and sulfur, and with one of the carbon atoms in said ring being unsubstituted or substituted with an oxo group, which heterocyclic ring is directly bonded or bonded via an alkylene group, to the remainder of the molecule; 4 is a cyclic tertiary amine which may contain one additional heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur wherein any sulfur present in the ring is thio or can be oxidized to sulfoxide or sulfur dioxide, by which said cyclic tertiary amine is directly attached to the remainder of the molecule or is attached through the linker —(CH 2 ) n N(R 5 )—; X is —C(O)N(R 5 )—, —(CH 2 ) m O—, —(CH 2 ) m N(R 5 )—, —N(R 5 )C(O)—, or —N(R 5 )(CH 2 ) m —; n, p and q are 1 to 4; and m is 1 or2; and to pharmaceutically acceptable acid addition salts thereof The compounds of this invention show a high affinity to the NK-1 receptor. They may be used for the treatment of diseases relating to NK1 antagonists.
    本发明涉及一般式的化合物1 其中,R为较低的烷基,较低的烷氧基,卤素或三氟甲基;R1为卤素或氢;当p为1时,除了上述取代基外,R1还可以与R1一起形成—CH═CH—CH═CH—;R2和R2'独立地为氢,卤素,三氟甲基,较低的烷氧基或氰基;当n为1时,除了上述取代基外,R2和R2'还可以形成—CH═CH—CH═CH—,未取代或被选自较低烷基或较低烷氧基的一到两个取代基取代;R3和R3'为氢,较低的烷基或与附加的碳原子一起形成环烷基;R4为氢,—N(R5)2,—N(R5)(CH2)nOH,—N(R5)S(O)2-较低烷基,N(R5)S(O)2-苯基,—N═CH—N(R5)2,—N(R5)C(O)R5;R5为氢,C3-6环烷基,苄基或较低的烷基;R6为羟基,较低的烷基;—(CH2)nCOO—(R5),—N(R5)CO-较低烷基,羟基-较低烷基;—(CH2)qCN;—(CH2)nO(CH2)nOH,—CHO或含有1至4个异原子的5或6元杂环,所述异原子选自氧,氮和硫,所述环中的一个碳原子未取代或被氧代基取代,该杂环通过烷基链直接键合或键合到分子的其余部分上;4为一个环状的三级胺,该胺可以包含一个额外的异原子,所述异原子选自氧,氮和硫,环中存在的任何硫为硫或可被氧化为亚硫酸盐或二氧化硫,该环状三级胺直接附着于分子的其余部分或通过连接剂—(CH2)nN(R5)—附着;X为—C(O)N(R5)—,—(CH2)mO—,—(CH2)mN(R5)—,—N(R5)C(O)—或—N(R5)(CH2)m—;n,p和q为1至4;m为1或2;以及其药学上可接受的酸盐。本发明的化合物表现出对NK-1受体的高亲和力。它们可用于治疗与NK1拮抗剂相关的疾病。
  • Arylalkylamine Compound and Process for Preparing the Same
    申请人:Miyazaki Hiroshi
    公开号:US20070225296A1
    公开(公告)日:2007-09-27
    The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R 1 : a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH 2 —, —CO—, —(CH 2 ) m —CO—, —CH(R 2 )—CO—, —(CH 2 ) p —Y—(C(R 3 )(R 4 )) q —CO—, —NH—CO— or —N(R 5 )—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO 2 —; R 2 : phenyl or lower alkyl; R 3 , R 4 : each independently represents hydrogen atom or lower alkyl; R 5 : lower alkyl; provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH 2 — or —CO—, R 1 is not naphthyl.
    本发明涉及一种由以下公式[I]表示的芳基烷基胺化合物或其药学上可接受的盐,其制备方法,以及上述化合物作为钙感受受体的激活化合物(CaSR激动剂),以及含有上述化合物作为有效成分的制药组合物等的用途。公式中的符号表示以下含义:Ar:此处为可选取代的芳基或可选取代的杂环芳基,其中杂环的环部分是一个含有1或2个杂原子的5-至6元单环杂环,与苯环融合;R1:选自可选取代的环烃基团和可选取代的杂环基团的群;n:1至3的整数;X:单键臂、—CH2—、—CO—、—(CH2)m—CO—、—CH(R2)—CO—、—(CH2)p—Y—(C(R3)(R4))q—CO—、—NH—CO—或—N(R5)—CO—;在上述各定义的X中,左端所描述的键臂表示与R1的键;m为1至3的整数;p为0至2的整数;q为0至2的整数;Y:—O—或—SO2—;R2:苯基或低碳烷基;R3、R4:各自独立地表示氢原子或低碳烷基;R5:低碳烷基;前提是由R1表示的基团的环部分既不是萘亚甲基也不是其部分饱和基团,且当X为—CH2—或—CO—时,R1不是萘基。
  • Process for the preparation of pyridine derivatives
    申请人:Hoffman-La Roche Inc.
    公开号:US06303790B1
    公开(公告)日:2001-10-16
    A process is described for preparing certain 4-alkyl- or 4-aryl-pyridine derivatives.
    描述了一种制备某些4-烷基或4-芳基吡啶衍生物的过程。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-